Year: 2012
Type: article
Abstract: Pharoah et al., Nakamura et al., and Stanton have questioned the validity of two recent articles published in the Journal ( 1 , 2 ). They specifically question the genotyping quality in the Breast International Group (BIG) 1-98 study ( 1 ). Nakamura et al., in fact, urge the retraction of the BIG 1-98 study and reanalysis of all studies utilizing tumor DNA for genotyping. We welcome the discourse that comes with comprehensive reporting of results as a valuable part of peer review. We too are keen proponents of personalized medicine. However, we believe that adopting a new test into standard clinical care requires high levels of evidence demonstrating clinical utility. We were disappointed that the results of these two investigations did not support the hypothesis that CYP2D6 genotype was associated with the outcome of postmenopausal women with early breast cancer treated with tamoxifen. We stand firmly behind the quality of methodology of the BIG 1-98 study, the contribution of our results to the body of literature, and the value that the two investigations ( 1 , 2 ) together bring to informing the care of patients with breast cancer.
DOI: 10.1093/jnci/djs313
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4232066842